John Tu, MD
University of Rochester
Department of Dermatology
1983 B.A., Biology, Molecular Biology Advanced Degree
Program, The Johns Hopkins University, Baltimore, MD
1987 M.S., Microbiology and Immunology, Albert Einstein
College of Medicine, Bronx, NY
1994 M.D., Albert Einstein College of Medicine, Bronx, NY
2002- M.S., Optics (Candidate), Institute of Optics, University of
Rochester, Rochester, NY
1994-1995 Intern in General Internal Medicine, Center for the Health Sciences, University of California, Los Angeles, Los Angeles, CA
1995-1997 Resident in Dermatology, Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO
1997-1998 Chief Resident in Dermatology, Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO
1998-2000 Research Fellow, Wellman Laboratories of Photomedicine, Department of Dermatology, Massachusetts General Hospital, Boston, MA
2000-2002 Research Fellow, Body Imaging Laboratory, University of Rochester School of Medicine & Dentistry, Department of Dermatology, Rochester, NY
2002-2005 Wilmot Cancer Research Fellow, University of Rochester Medical Center, Rochester, NY
Spring 1994: Molecular biology of RU486, University of Paris Academic Exchange Program, Laboratory of Dr. Étienne-Émile Baulieu, Université de Paris, Le Kremlin-Bicêtre, Paris, France
1998-2000: Gross and microscopic autofluorescence imaging of non-melanoma skin cancers, Laboratory of Nikiforos Kollias, Ph.D., and R. Rox Anderson, M.D., Wellman Laboratories of Photomedicine, Department of Dermatology, Massachusetts General Hospital, Boston, MA
2000-: Application of non-invasive autofluorescence imaging to diagnosis of non-melanoma skin cancers, Body Imaging Laboratory, Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY
2004-2005: Phase III clinical trial: celecoxib chemoprevention of actinic keratosis. Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY
2002-2005: Wilmot Cancer Fellow, University of Rochester Medical Center, Rochester, NY
1. Rodriguez-Burford, C., Mercurio, M., Tu, J.H., Carey, D., Han, R., Gordon, G., Niwas S., Bell, W., Elmets, C.A., Grizzle, W., Pentland, A.P.: Selective COX-2 inhibition produces heterogeneous erythema response to UV-irradiation. J Invest Dermat. 125(6):1317-20, 2005.
2. Brancaleon, L., Durkin, A.J., Tu, J.H., Menaker, G., Fallon, J.D., Kollias, N. In vivo fluorescence spectroscopy of nonmelanoma skin cancer. Photochem Photobiol 2001; 73(2):178-183.
3. Tu, J.H. and Eisen, A.Z., Scleroderma, in Fitzpatrick's Dermatology in General Medicine. 5th Ed., Freedberg et al., Eds., New York, McGraw-Hill, pp. 2023-2033.
4. Tu, J.H., Mann, C., and Breer, W. Acute onset of dermal nodules in a patient with multiple myeloma on chemotherapy. Mini-Consults in Dermatology. Volume V. CD-ROM. from Gross and Microscopic Symposium. 1998 American Academy of Dermatology Annual Meeting. Orlando, FL.
5. Rosenstreich, D.L., Tu, J.H., Kinkade, P.R., Maurer-Fogy, I., Kahn, J., Barton, R.W., and Farina, P.R. 1987. A human urine-derived interleukin-1 inhibitor: Homology with deoxyribonuclease I. J Exp Med 168:1767-1779.
6. Rosenstreich, D.L., Yost, S.L., Brown, K.M., and Tu, J.H. 1987. Interleukins and interleukin inhibitors. Einstein Quart J Biol Med 34:45-55.
7. Liao, Z., Tu, J.H., Small, C.B., Schnipper, S.M., and Rosenstreich, D.L. 1993. Increased urine interleukin-1 levels in aging. Gerontol 39:19-27.